Welcome to our dedicated page for CytomX Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
CytomX Therapeutics director Su Zhen received a grant of stock options covering 59,000 shares of common stock. The options were awarded at an exercise price of $2.96 per share and are held directly. Following this grant, Su Zhen holds stock options for 59,000 shares.
According to the vesting terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that vesting date.
CytomX Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved several governance and equity-related proposals. The company later filed a charter amendment to reflect these changes.
Stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 6,500,000 shares, and an amendment to the Amended and Restated Employee Stock Purchase Plan to increase shares authorized thereunder by 1,000,000 shares. Both amendments were previously adopted by the board and became effective upon stockholder approval.
Stockholders also approved a charter amendment increasing the authorized number of shares of common stock from 300,000,000 to 600,000,000 shares. All management proposals, including the election of two Class II directors, ratification of Ernst & Young LLP as auditor, executive compensation on an advisory basis, and holding future say-on-pay votes every year, received sufficient support, with broker non-votes recorded where applicable.
CytomX Therapeutics director Matthew P. Young received a grant of stock options representing rights to buy 59,000 shares of common stock at an exercise price of $2.96 per share.
All 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of CytomX stockholders, as long as he continues serving as a director until that vesting date.
CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036. All 59,000 options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continuous service as a director.
CytomX Therapeutics, Inc. director James R. Meyers received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the award terms, 100% of the options will vest on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds 59,000 derivative securities directly, reflecting a compensation-related award rather than an open‑market purchase.
CytomX Therapeutics director Halley E. Gilbert received a new stock option grant for 59,000 shares of common stock at an exercise price of $2.96 per share. This is a compensation-related award, not an open-market purchase or sale.
The option vests in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that date. Following this grant, Gilbert is reported as holding 59,000 stock options directly.
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or the 2027 annual meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds options for 59,000 shares directly.
CytomX Therapeutics, Inc. reported that director Elaine V. Jones received a stock option grant. She was awarded options to acquire 59,000 shares of common stock at an exercise price of $2.96 per share, giving her rights to buy shares at that price in the future.
After this grant, she holds 59,000 derivative securities linked to common stock. According to the terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 annual stockholder meeting, assuming she continues serving as a director until that vesting date.
CytomX Therapeutics Chief Financial Officer Christopher Ogden reported an open-market sale of 1,624 shares of common stock on June 15, 2026 at an average price of $3.05 per share. According to the disclosure, the shares were sold solely to satisfy tax and other government withholding obligations arising from the vesting of restricted stock units, so the transaction reflects a tax-related event rather than a discretionary portfolio move.
After this sale, Ogden holds a total of 295,324 shares of CytomX Therapeutics common stock, including 167,249 restricted stock units that will convert into shares as they vest over time. The sale represents a small portion of his overall direct equity position, indicating that he retains substantial exposure to the company’s stock following this routine tax-withholding transaction.
CytomX Therapeutics updated its cancer drug collaboration with Regeneron through Amendment No. 4 to their 2022 Collaboration and License Agreement. The amendment, effective May 31, 2026, extends the period in which Regeneron can select additional drug programs and allows for up to eight more collaboration programs.
Regeneron has already nominated the first two of these additional programs, which entitle CytomX to receive $37.0 million in aggregate target nomination payments. Across all potential programs, the Agreement provides for up to approximately $4 billion in target nomination, preclinical, clinical, regulatory and commercial milestone payments, while previously disclosed tiered royalty terms remain unchanged.